Misplaced Pages

CYB210010

Clinical data
Other names	CYB-210010; CYB-2108; CYB2108
Identifiers
IUPAC name 2-ethanamine
PubChem CID	168072159
Chemical and physical data
Formula	C11H14F3NO2S
Molar mass	281.29 g·mol
3D model (JSmol)	Interactive image
SMILES COC1=CC(=C(C=C1CCN)OC)SC(F)(F)F
InChI InChI=1S/C11H14F3NO2S/c1-16-8-6-10(18-11(12,13)14)9(17-2)5-7(8)3-4-15/h5-6H,3-4,15H2,1-2H3 Key:VOGDBAZLGHXJBS-UHFFFAOYSA-N

CYB210010, also known as 2C-T-TFM, is a lesser-known psychedelic drug of the phenethylamine family related to compounds such as 2C-T and 2C-T-21.

Alexander Shulgin attempted to synthesise this compound in the 1990s, and mentions it in his book PiHKAL under the entry for 2C-T-21, but was unsuccessful in producing a key intermediate and never assigned it a 2C-T number. This compound was ultimately first synthesised by Geoffrey Varty and colleagues at Irish biopharmaceutical company Cybin in 2023.

It has a K_i of 0.35 nM at the serotonin 5-HT_2A receptor, and an EC₅₀Tooltip half-maximal effective concentration of 4.1 nM at the serotonin 5-HT_2A receptor and 7.3 nM at the serotonin 5-HT_2C receptor, compared to 88 nM at the serotonin 5-HT_2B receptor. It is a potent, selective, long acting, and orally active agonist for the serotonin 5-HT_2A and 5-HT_2C receptors and produces psychedelic-like responding in several different animal species. It has only been studied preclinically as of 2024 and is not known to have been tested in humans.

Related drugs include the deuterated phenethylamine CYB005 and the deuterated substituted tryptamines CYB003 and CYB004.

See also

• 2C (psychedelics)
• 2C-T-21.5
• 2C-T-28
• 2C-TFM
• 2C-TFE
• 3C-DFE
• DOPF
• Tiflorex
• Trifluoromescaline

References

1. "2-[2,5-Dimethoxy-4-(trifluoromethylsulfanyl)phenyl]ethanamine". PubChem. Retrieved 10 November 2024.
2. ^ Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, et al. (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". Journal of Medicinal Chemistry. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID 38593423.
3. ^ Palfreyman M, Varty G, Canal C, Hartsel J, Tyagi R, Avery K, et al. (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P405. Discovery and Preclinical Characterization of the Phenylalkylamine, CYB210010, a Potent and Long-Acting Serotonin 5-HT2A Receptor Agonist". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (299–299. doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
4. WO 2023156450, Nivorozhkin A, JA Hartsel, Canal CE, Salituro FG, Mueller TA, Greene BJ, Belser A, Avery KL, Reichelt AC, Varty GB, Palfreyman M, "Therapeutic phenethylamine compositions and methods of use", published 24 August 2023, assigned to Cybin Irl Limited 
5. Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, et al. (December 2022). "Key Characteristics and Development of Psychoceuticals: A Review". Int J Mol Sci. 23 (24): 15777. doi:10.3390/ijms232415777. PMC 9779201. PMID 36555419.
6. Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nat Biotechnol. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID 38831049.

• 5-HT2A agonists
• 5-HT2B agonists
• 5-HT2C agonists
• 2C (psychedelics)
• Amines
• Entheogens
• Experimental hallucinogens
• Methoxy compounds
• Thioethers
• Trifluoromethylthio compounds